Why the new GLP-1 pill is such a big deal

Key Points:

• The FDA has approved Eli Lilly’s oral GLP-1 pill, Foundayo, marking a significant shift from injectable weight-loss drugs to a more convenient daily pill form, potentially increasing patient adherence and accessibility.
• Unlike Novo Nordisk’s peptide-based Wegovy pill, Lilly’s small-molecule pill is easier to manufacture, has fewer special administration requirements, and may reduce supply chain issues, making it a promising option for primary care.
• Clinical trials show the Lilly pill results in an average 12% body weight loss, comparable to some existing injectables, but its main advantage lies in convenience rather than superior efficacy.
• Cost remains a barrier, with the pill priced at $149 to $299 per month; while Medicare and some insurers cover it, access for lower-income patients is still limited, highlighting ongoing challenges in equitable obesity treatment.
• Experts emphasize the need for comprehensive patient support and healthcare system adaptation to maximize benefits and manage side effects, as well as the likelihood that future personalized GLP-1 treatments will continue to evolve.